KLSE (MYR): BIOHLDG (0179)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.07
Today's Change
0.00 (0.00%)
Day's Change
0.065 - 0.07
Trading Volume
59,100
Market Cap
98 Million
NOSH
1,406 Million
Latest Quarter
30-Jun-2024 [#2]
Announcement Date
30-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
30-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
-5.98% | -119.70%
Revenue | NP to SH
59,224.000 | -31,852.000
RPS | P/RPS
4.21 Cent | 1.66
EPS | P/E | EY
-2.26 Cent | -3.09 | -32.35%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.09 | 0.74
QoQ | YoY
-14.51% | 42.12%
NP Margin | ROE
-58.55% | -23.96%
F.Y. | Ann. Date
30-Jun-2024 | 30-Aug-2024
Latest Audited Result
31-Dec-2023
Announcement Date
30-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
30-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Revenue | NP to SH
46,084.000 | -38,547.000
RPS | P/RPS
3.28 Cent | 2.14
EPS | P/E | EY
-2.74 Cent | -2.55 | -39.15%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
0.10 | 0.72
YoY
17.4%
NP Margin | ROE
-86.99% | -28.25%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Revenue | NP to SH
60,368.000 | -29,336.000
RPS | P/RPS
4.29 Cent | 1.63
EPS | P/E | EY
-2.08 Cent | -3.36 | -29.80%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-4.95% | 27.25%
NP Margin | ROE
-50.02% | -22.07%
F.Y. | Ann. Date
30-Jun-2024 | 30-Aug-2024
Trailing 4 Quarters | Trailing 8 Quarters | |||
---|---|---|---|---|
Available Quarters | 4 Quarters | 8 Quarters | ||
Continuous Quarters Of Revenue Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Total Positive Profit Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Positive Profit | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Profit Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Adjusted EPS Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Total Dividend Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Average ROE | -5.79% | -7.06% | ||
Average Net Profit Margin | -63.85% | -107.16% |
Last 5 Financial Years | Last 10 Financial Years | |||
---|---|---|---|---|
Available Years | 5 Years | 10 Years | ||
Continuous Quarters Of Revenue Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Total Positive Profit Years | 1 / 5 | 20.00% | 6 / 10 | 60.00% |
Continuous Quarters Of Positive Profit | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Continuous Quarters Of Profit Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Continuous Quarters Of Adjusted EPS Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
Total Dividend Years | 0 / 5 | 0.00% | 3 / 10 | 30.00% |
Continuous Quarters Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Continuous Quarters Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
Average ROE | -15.05% | -3.19% | ||
Average Net Profit Margin | -62.69% | -21.98% |
T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
---|---|---|---|---|---|
Revenue | 59,224 | 60,368 | 46,084 | 50,610 | 55,450 |
NP to SH | -31,852 | -29,336 | -38,547 | -7,310 | -23,045 |
Dividend | 0 | 0 | 0 | 219 | 0 |
Adjusted EPS | -2.26 | -2.08 | -2.74 | -0.52 | -1.64 |
Adjusted DPS | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
---|---|---|---|---|---|
Revenue | 217.95% | 169.73% | 77.09% | 55.09% | 94.15% |
NP to Owner | -5.98% | -119.70% | 27.25% | 6.99% | 31.81% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | -6.00% | -121.13% | 27.45% | 6.66% | 31.43% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 28.51% | 6.80% | 17.02% | 31.00% | 8.87% | 19.28% | 28.89% | -16.89% | -8.94% |
NP to Owner | 17.37% | -38.21% | -335.72% | 23.90% | -27.30% | -301.30% | 17.40% | -67.27% | -427.30% |
Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Adjusted EPS | 17.54% | -37.93% | -334.83% | 24.11% | -26.95% | -300.19% | 17.40% | -67.27% | -427.30% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
worry not. just sell to the market. this is just the warrant rights you entitle for holding on to mother.
quickly sell it while it is still available (0.005). later probably worth nothing
2024-01-12 14:08
to subscribe the warrants need to put in 13.5 sens, mean the mother share will go higher than 13.5 sens soon ?
2024-01-12 15:05
check the history of the company. see how was the warrant holder and pa holder being treated. avoid this counter
2024-01-12 15:16
i'm a newbie @this counter. Feels interested @ this company's warrant issuance....
Anyways, I think base on my study on Biohldg fundamental, I made a conclusion that this company won't be succumb to GN3 in a near future. The company is improving its pofitabilty...
1. NTA 10.85 sen.
2. NOSH 1.406 bilion.
3. EQUITY
Share capital RM 186,014,000
Reserves (RM 39,795,000)
Equity attributable to owners of the parent RM 146,219,000
Non-controlling interests RM 3,353,000
TOTAL EQUITY RM 149,572,000
4. Cash and Cash Equivalent:
Fixed deposit with licensed bank RM 1,018,000
Cash and bank balances RM 9,597,000
5. Assets:
Non-current Assets RM 138,443,000
(Note: Including investment in quoted shares RM 23,532,000)
Current Assets RM 56,258,000
TOTAL ASSETS RM 194,701,000
6. Liabilities:
Current Liabilities RM 12,385,000
Non-current liabilities RM 32,744,000
TOTAL LIABILITIES RM 45,129,000
7. Last QR result-Net loss (RM2,760,000)
Note 1:
The Group’s current quarter revenue for the financial period ended 30 September 2023 (“3QFY23”) grew by 61.3% year-on-year (“YoY”) to RM11.7 million, as compared to RM7.3 million in the preceding year’s corresponding quarter (“3QFY22”). The growth was driven by improved performance across all the Group’s segments
Note 2:
The Group’s revenue for the 3QFY23 increased by 37.7% to RM11.7 million, against RM8.5 million in the second (2nd) quarter ended 30 June 2023.
Note 3:
Meanwhile, turnover for the Group’s supply of health foods to China more than doubled to RM3.0 million in 3QFY23 (2QFY23: RM1.4 million) as deliveries to customers picked up. For our retail pharmacy business, revenue grew by 76.8% to RM5.4 million, from RM3.1 million in 2QFY23, on the back of contributions from newly opened pharmacy outlets.
2024-01-15 11:42
Important dates to read and digest. For those who want to speculate, can use it as an important information. TAYOR.
---------------------
Date for commencement of trading of rights 12 Jan 2024
Date for cessation of trading of rights 19 Jan 2024
Date for announcement of final subscription result and basis of allotment of excess Rights Securities 06 Feb 2024
Last date and time for :
Sale of provisional allotment of rights 18 Jan 2024 05:00 PM
Transfer of provisional allotment of rights 22 Jan 2024 04:30 PM
Acceptance and Payment 29 Jan 2024 05:00 PM
Excess share application and payment 29 Jan 2024 05:00 PM
Available/Listing Date 14 Feb 2024
2024-01-15 12:54
I like the venture into pharmacy retain store biz instead of just focusing on manufacturing and supplying health supplement
2024-01-15 22:37
To make sure the warrant issuance exercise successful, the price of the mother share SHOULD be more than 13.5 sen!!!
Just my DREAM... TAYOR
18 Jan - 29 Jan for me are the important dates..... to monitor
2024-01-17 21:52
Hope in incoming one or two days of trading, it can test the highest price in a year @14 sen. TAYOR
https://www.tradingview.com/symbols/MYX-BIOHLDG/technicals/
2024-01-19 20:43
Note 3 from latest financial reports:
For our retail pharmacy business, revenue grew by 76.8% to RM5.4 million, from RM3.1 million in 2QFY23, on the back of contributions from newly opened pharmacy outlets.
Newly opened pharmacy outlets? Let's dig some info:
1. Constant Pharmacy has been around for about 20 years now. It is a government-linked brand which enjoys support from Bioalpha Holdings Berhad. To date, it has grown to more than 13 outlets mostly around the Klang Valley.
Google search returned 15 outlets, and this is for over 20 years? AA pharmacy, Alpro pharmacy, Multicare pharmacy and Health Lane pharmacy which are not well known has at least 50 or more shops in Malaysia.
2. Constant Pharmacy in Shopee has extremely low volume of overall items sold:
-- Top item is apple cider vinegar sold for 2900+
-- Second top item is Panadol for 300+
Shopee may not constitute a big part of the sales, but still a very sad number if you look at the overall number of items sold.
3. LinkedIn company size for Constant pharmacy shows:
-- 51-200 employees
-- 39 associated members (members who’ve listed Constant Pharmacy as their current workplace on their profile.)
AA pharmacy, Alpro pharmacy, Multicare pharmacy and Health Lane pharmacy has at least 4 times in terms of associated members, and also at least 200 to >1000 employees.
2024-01-25 07:49
Note 3 from latest financial reports:
Meanwhile, turnover for the Group’s supply of health foods to China more than doubled to RM3.0 million in 3QFY23 (2QFY23: RM1.4 million) as deliveries to customers picked up.
In the China agreement, BIO announced the contract to be worth $$$ per year:
The value of supplying health food and nutritional meals supplied is approximately RMB700,000,000 per year (equivalent to RM426,700,000).
In a query from Bursa, BIO replied:
Query: The basis and justification in arriving the value of the health food and nutritional meals to be supplied of approximately RMB700,000,000 per year (equivalent to RM426,700,000).
Reply: The supply contract value of RMB700,000,000 was offered by GYHX based on their requirements to meet the market consumption (public and private sector) based on its high population and health conscious awareness of the health food and nutritional meals.
The turnover of one quarter in 3QFY23 is 3 million, and yet the estimated supply value is 106 million a quarter?
2024-01-25 08:11
The Group’s QR3 2023 revenue based on the geographical location of its customers is presented as follows:
Malaysia RM8,633,000
Indonesia RM14,000
China RM3,029,000
Others RM44,000
Total RM11,720,000
Note:
Revenue from Malaysia QR3 2023 up 40% from RM5,133,000 in QR3 2022.
Revenue from China also up 56% from RM1,943,000 in QR3 2022.
2024-01-25 15:28
the accts figures mainly made by Accountant CEO to attract water fish lol....
2024-01-30 17:02
Burnt some here......
For the sake of an experiment on a new counter..
Sorry guys... In facts, the information is still valid..
But this counter is not suitable for me to play... He He He
2024-01-30 20:31
A lot of so called MOU with china ,end up tin Kosong …pharmaceutical also can’t compete with BIG.caring ..
2024-03-07 19:49
FOR NEWBIES
NOSH = 1,406,491,096
PA = 403,559,464
WB = 526,099,537
https://www.klsescreener.com/v2/stocks/view/0179/bioalpha-holdings-berhad
Look for capital changes in above link
==========
Take note of NOSH exceeding 1 BILLION shares due to directors massive fund raising via shares, warrant and PA issuance
Multi year loss making company
2024-06-18 12:03
FOR NEWBIES
List of high NOSH penny stocks with shares consolidation :-
2024 in progress - MQTECH, XOX, DESTINI, VIZIONE, KGROUP
2024 completed - AEM, AT, FINTEC, TECHNAX, MLAB, BPURI,
2023 completed = JOE, ICON, MMAG, KOMARK, GOCEAN, AIM, DOLPHIN, DGB, VSOLAR, MERIDIAN, PASUKGB, EDUSPEC
2022 - YONGTAI, DIGISTA, MTRONIC, AGES, IDMENSN, KANGER, AAX, LKL, MNC, NEXGRAM, IMPIANA, FAST
BEFORE 2022 - PWORTH, PDZ, LAMBO, PASUKGB, MTOUCHE, SANICHI, VC, TRIVE, VINVEST, ICON, MLAB, NETX,.........
Retail investors trapped at high price incurred huge losses caused by share consolidation
2024-06-28 14:15
FOR NEWBIES
NOSH = 1,406,491,096
PA = 403,559,464
WB = 526,099,537
Multi year loss making company since 2020
==================
Announced EX Date Subject Ratio Offer
22 Dec 2023 10 Jan 2024 Rights Issue (warrant) 3.0000 : 8.000 0.0350
09 Apr 2021 22 Apr 2021 Rights Issue 1.0000 : 6.0000 0.0200 View
09 Apr 2021 22 Apr 2021 Rights Issue 1.0000 : 15.0000 0.2000 View
==================
https://www.klsescreener.com/v2/stocks/view/0179/bioalpha-holdings-berhad
Look for capital changes in above link
==========
Take note of NOSH exceeding 1 BILLION shares due to directors massive fund raising via shares, warrant and PA issuance
Be careful of directors doing frequent fund raising via shares issuance to PA, ESOS, RI,
==================
Continue to monitor
quarterly results
directors plan for utilisation of company funds
directors plan for more fund raising via shares issuance to PP, ESOS or asset acquisition
2 months ago
Newbies don't touch this stock. Had bought this counter during the pandemic times when healthcare theme was in play, speculative rise and fall, while insiders keep dumping their shares. Keep raising funds through RI and losses year after year. Bought only for speculative play.
2 months ago
Possible.. last time hear a lot of China business potential.. now go Langkawi
2 months ago
VinAlag
wait im a bit lost...i didnt subsribe for it...it just appeared in my trading account..will they be back charging for it? im a bit lost sorry
2024-01-12 13:52